neurimmune.com
Neurimmune - HomeSevere and Rare Diseases. Severe and Rare Diseases. Phase 3 clinical trials. Program for Parkinson in Phase 1. Creating an entirely novel. Generation of drugs with. Excellent safety and efficacy. January 25, 2018. In January 2018, Biogen dosed the first patient in the Phase 2 SPARK study of BIIB054 (anti-alpha-synuclein antibody) in Parkinson's disease. November 9, 2017. Neurimmune Announces Collaboration with Ono Pharmaceutical in Neurodegenerative Diseases Field. October 24, 2017. Neurimmune’s program ...
http://www.neurimmune.com/
SOCIAL ENGAGEMENT